The ATLANTIC study demonstrated that an objective response was achieved in 12.2% patients who had EGFR+/ALK+ NSCLC with tumor cell PD‐L1 expression ≥25%, treated with durvalumab (anti‐PD‐L1).22 The gene discussed is ALK; the disease is non-small cell lung carcinoma.